PFAS Exposure and Endocrine Disruption Among Women
JAMA Network Open · 05.12.2025 · 8 (12) · e2539425
DOI: 10.1001/jamanetworkopen.2025.39425 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 05.12.2025. Verfasst von Rezaul Karim Ripon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Environmental Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cross-sectional study investigates the association between perfluoroalkyl and polyfluoroalkyl substances (PFAS) exposure and endocrine disruption among US women.
Autor:innen und Institutionen
- Environmental Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
- McHigher Center for Health Research, Dhaka, Bangladesh.
- Public Health Literacy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Public Health and Informatics, Jahangirnagar University, Dhaka, Bangladesh.
- Public Health Literacy, UT Southwestern, Miami, Florida.
- Pharmamanagement EAS De RL, Mexico City, Mexico.
Zitieren
APA
Ripon, R. K., Hossain, M. J., Volquez, M., Meda-Monzon, E., Saunik, S., & Prasad, N. (2025). PFAS Exposure and Endocrine Disruption Among Women. JAMA Network Open, 8(12), e2539425. https://doi.org/10.1001/jamanetworkopen.2025.39425
Vancouver
Ripon RK, Hossain MJ, Volquez M, Meda-Monzon E, Saunik S, Prasad N. PFAS Exposure and Endocrine Disruption Among Women. JAMA Network Open. 2025;8(12):e2539425. doi:10.1001/jamanetworkopen.2025.39425
BibTeX
@article{Ripon2025,
author = {Ripon, Rezaul Karim and Hossain, Md Jamil and Volquez, Mayra and Meda-Monzon, Elizabeth and Saunik, Sujata and Prasad, Narayana},
title = {PFAS Exposure and Endocrine Disruption Among Women},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {12},
pages = {e2539425},
doi = {10.1001/jamanetworkopen.2025.39425}
}
EUVIMED